Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer

American Journal of Pathology

Volumn 178, Issue 2, 2011, Pages 525-536

  Vainio, Paula ^a   Gupta, Santosh ^a   Ketola, Kirsi ^a   Mirtti, Tuomas ^b   Mpindi, John Patrick ^c   Kohonen, Pekka ^a   Fey, Vidal ^d   Perälä, Merja ^d   Smit, Frank ^e   Verhaegh, Gerald ^e   Schalken, Jack ^e   Alanen, Kalle A ^b   Kallioniemi, Olli ^a,c,d   Iljin, Kristiina ^a,d  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ANDROGEN RECEPTOR; ARACHIDONIC ACID; BIOLOGICAL MARKER; CYTOCHROME P450 4F8; EPOXIDE HYDROLASE 2; FLUTAMIDE; MESSENGER RNA; PHOSPHOLIPASE A2; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOINFORMATICS; CANCER CELL; CARCINOGENESIS; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME INHIBITION; FUNCTIONAL GENOMICS; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; ONCOGENE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VALIDATION PROCESS;

EID: 79951825010     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.10.002     Document Type: Article

References (54)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; ; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512 (Pubitemid 39315317)
2. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL: Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004, 164:217-227 (Pubitemid 38364606)
3. Pienta KJ, Bradley D: Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006, 12:1665-1671
4. Taichman RS, Loberg RD, Mehra R, Pienta KJ: The evolving biology and treatment of prostate cancer. J Clin Invest 2007, 117:2351-2361 (Pubitemid 47494332)
5. Dillard PR, Lin MF, Khan SA: Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008;295:115-120
6. Attard G, Reid AH, Olmos D, de Bono JS: Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009, 69:4937-4940
7. Patel MI, Kurek C, Dong Q: The arachidonic acid pathway and its role in prostate cancer development and progression. J Urol 2008, 179:1668-1675
8. Chaudry A, McClinton S, Moffat LE, Wahle KW: Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer 1991, 64:1157-1160
9. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD: Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 1995, 87:1456-1462
10. Ghosh J, Myers CE: Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun 1997, 235:418-423 (Pubitemid 27313723)
11. Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM, Gleave ME, Nelson CC: Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate 2010, 70:239-251
12. Fürstenberger G, Krieg P, Müller-Decker K, Habenicht AJ: What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer 2006, 119:2247-2254
13. Matsuyama M, Yoshimura R: The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer. Biologics 2008, 2:725-732
14. Wang D, Dubois RN: Eicosanoids and cancer. Nat Rev Cancer 2010, 10:181-193
15. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000, 275:11397-11403 (Pubitemid 30212792)
16. Narayanan BA, Narayanan NK, Pittman B, Reddy BS: Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004, 10:7727-7737 (Pubitemid 39557538)
17. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ: Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005, 11:1999-2007 (Pubitemid 40471866)
18. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR and Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302-1308
19. Moretti RM, Montagnani Marelli M, Sala A, Motta M, Limonta P: Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. Int J Cancer 2004, 112:87-93 (Pubitemid 39249495)
20. Sved P, Scott KF, McLeod D, King NJ, Singh J, Tsatralis T, Nikolov B, Boulas J, Nallan L, Gelb MH, Sajinovic M, Graham GG, Russell PJ, Dong Q: Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res 2004, 64:6934-6940 (Pubitemid 39331002)
21. Chaudry AA, Wahle KW, McClinton S, Moffat LE: Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994, 57:176-180 (Pubitemid 24144205)
22. Endsley MP, Thill R, Choudhry I, Williams CL, Kajdacsy-Balla A, Campbell WB, Nithipatikom K: Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer 2008, 123:1318-1326
23. Jain S, Chakraborty G, Raja R, Kale S, Kundu GC: Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008, 68:7750-7759
24. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, Pisto T, Saarela M, Skotheim RI, Björkman M, Mpindi JP, Haapa-Paananen S, Vainio P, Edgren H, Wolf M, Astola J, Nees M, Hautaniemi S, Kallioniemi O: Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol 2008, 9:R139
25. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, Nees M, Kallioniemi O: TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006, 66:10242-10246 (Pubitemid 44799738)
26. Harris SE, Rong Z, Harris MA, Lubahn DB: Androgen receptor in human prostate carcinoma LNCaP/ADEP cells contains a mutation which alters the specificity of the steroid dependent transcriptional activation region. Program and Abstracts, 72nd Annual Meeting of the Endocrine Society, Atlanta, GA. 1990:93
27. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL, Pienta KJ: VCaP, a cell-based model system of human prostate cancer. In Vivo 2001, 15:163-168 (Pubitemid 32328191)
28. Brideau C, Gunter B, Pikounis B Liaw A: Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen 2003, 6:634-647
29. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM: ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6 (Pubitemid 38391943)
30. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH: Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004, 22(14):2790-2799 (Pubitemid 41079896)
31. Dong Q, Patel M, Scott KF, Graham GG, Russell PJ, Sved P: Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett 2006, 240:9-16 (Pubitemid 44037166)
32. Tang DG, Bhatia B, Tang S, Schneider-Broussard R: 15-Lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size). Prostaglandins Other Lipid Mediat 2007;82:135-146
33. Stafforini DM: Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 2009, 23:73-83
34. Bylund J, Hidestrand M, Ingelman-Sundberg M, Oliw EH: Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides. J Biol Chem 2000, 275:21844-21849 (Pubitemid 30621753)
35. Thomassen M, Tan Q, Kruse TA: Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis [Erratum appeared in Breast Cancer Res Treat 2009, 113:251-252]. Cancer Res Treat 2009, 113:239-249
36. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY, Koeffler HP: 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006, 66:7818-7823 (Pubitemid 44289243)
37. Huang G, Eisenberg R, Yan M, Monti S, Lawrence E, Fu P, Walbroehl J, Löwenberg E, Golub T, Merchan J, Tenen DG, Markowitz SD, Halmos B: 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res 2008, 68:5040-5048
38. Thiel A, Ganesan A, Mrena J, Junnila S, Nykänen A, Hemmes A, Tai HH, Monni O, Kokkola A, Haglund C, Petrova TV, Ristimäki A: 15-Hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res 2009, 15:4572-4580
39. Tseng-Rogenski S, Gee J, Ignatoski KW, Kunju LP, Bucheit A, Kintner HJ, Morris D, Tallman C, Evron J, Wood CG, Grossman HB, Lee CT, Liebert M: Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am J Pathol 2010, 176:1462-1468
40. Enayetallah AE, French RA, Barber M, Grant DF: Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues. J Histochem Cytochem 2006, 54:329-335 (Pubitemid 43291277)
41. Enayetallah AE, French RA, Grant DF: Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. J Mol Histol 2006, 37:133-141
42. Foulks JM, Weyrich AS, Zimmerman GA, McIntyre TM: A yeast PAF acetylhydrolase ortholog suppresses oxidative death. Free Radic Biol Med 2008, 45:434-442
43. Kim JY, Hyun YJ, Jang Y, Lee BK, Chae JS, Kim SE, Yeo HY, Jeong TS, Jeon DW, Lee JH: Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. Am J Clin Nutr 2008, 88:630-637
44. Kang YJ: Metallothionein redox cycle and function. Exp Biol Med (Maywood) 2006, 231:1459-1467
45. Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, GrafströM RC, Perälä M, Kallioniemi O: High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 2009, 15:6070-6078
46. Luria A, Morisseau C, Tsai HJ, Yang J, Inceoglu B, De Taeye B, Watkins SM, Wiest MM, German JB, Hammock BD: Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase. Am J Physiol Endocrinol Metab 2009, 297:E375-E383
47. Woodward DF, Protzman CE, Krauss AH, Williams LS: Identification of 19 (R)-OH prostaglandin E2 as a selective prostanoid EP2-receptor agonist. Prostaglandins 1993, 46:371-383 (Pubitemid 23308673)
48. Wang X, Klein RD: Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway. Mol Carcinog 2007, 46:912-923 (Pubitemid 350058411)
49. Newman JW, Morisseau C, Harris TR, Hammock BD: The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci USA 2003, 100:1558-1563 (Pubitemid 36254486)
50. Pinot F, Grant DF, Spearow JL, Parker AG, Hammock BD: Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice. Biochem Pharmacol 1995, 50:501-508
51. Tong M, Tai HH: Induction of NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells. Biochem Biophys Res Commun 2000, 276:77-81
52. Mirtti T, Laine VJ, Hiekkanen H, Hurme S, Rowe O, Nevalainen TJ, Kallajoki M, Alanen K: Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality. APMIS 2009, 117:151-161
53. Tang Y, Wang MT, Chen Y, Yang D, Che M, Honn KV, Akers GD, Johnson SR, Nie D: Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer. Int J Cancer 2009, 124:1545-1551
54. Bhatia B, Maldonado CJ, Tang S, Chandra D, Klein RD, Chopra D, Shappell SB, Yang P, Newman RA, Tang DG: Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. J Biol Chem 2003, 278:25091-25100 (Pubitemid 37548673)